Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- Myelodysplastic Syndromes
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
$0.00
The management of myelodysplastic syndromes (MDS) is complicated by the generally advanced age of the patients. The major clinical problems are morbidities caused by cytopenias and the potential for MDS to progress to acute myeloid leukemia. There are limited treatment options following disease progression, particularly for patients with disease refractory to hypomethylating agents. As new data emerge, it is important for clinicians to be aware of all the treatment options available so they can devise individualized therapeutic strategies and improve clinical outcomes.
- Multiple Myeloma
- 2.25 AAPA Category 1 CME credit
- 2.25 ACPE contact hours
- 2.25 AMA PRA Category 1 Credit™
- 2.25 ANCC contact hours
- 2.25 Participation
$0.00
With the introduction of many new therapies, the management of multiple myeloma (MM) is rapidly changing. A uniform treatment approach cannot be applied to all patients. Clinicians must understand the treatment evolution and guidelines for when to administer two-, three- or four-drug regimens as initial therapy in context of the patient's therapeutic and disease history. When the disease relapses, selecting the optimal therapies is a challenge. Recently, FDA expanded indications for use of CAR T-cell therapies in earlier lines of therapy in the relapsed/refractory setting.
- Acute Lymphoblastic Leukemia
- Multiple Myeloma
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
$0.00
As additional, more effective, and novel therapies are added to the repertoire of cancer therapy, there are increasing numbers of cancer survivors, and these survivors are living for longer periods of time from diagnosis. In the case of those diagnosed with multiple myeloma (MM), due to the growing number of treatment options and improved supportive care, patients are living longer, and MM is becoming more of chronic disease.
- Non-Hodgkin's Lymphoma
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
$0.00
Polatuzumab vedotin in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) has emerged as a new first-line therapy option for patients with advanced stage diffuse large B-cell lymphomas (DLBCL). The survival benefit was seen only in a subgroup of patients with non-bulky disease and activated B cell (ABC) subtype.
- Non-Hodgkin's Lymphoma
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
$0.00
The advent of novel targeted therapies represents a major paradigm shift for management of relapsed or refractory diffuse large B-cell lymphomas (DLBCL). Sequencing of treatment options for relapsed/refractory DLBCL are based on the timing of relapse and eligibility to receive transplant or chimeric antigen receptor (CAR) T-cell therapy. There is a clear need to educate clinicians about the use of novel targeted therapies in appropriately selected patients, the unique spectrum of treatment-related adverse events, and effective management strategies.
- Chronic Lymphocytic Leukemia
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
$0.00
The prognostic significance of molecular and cytogenetic variables vary depending on the treatment regimens and clinical outcomes being evaluated. A precise understanding of the prognostic significance of these variables is essential for the appropriate selection of patients who might benefit from specific targeted therapies with small molecule inhibitors.
- Hodgkin Lymphoma
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
$0.00
Given the high cure rate of classic Hodgkin lymphoma, clinical trials strive to reduce potential long-term toxicities of treatment. Novel agents such as antibody-drug conjugates and immune checkpoint inhibitors have become part of front-line treatment recommendations for advanced stage classic Hodgkin lymphoma over the last several years, allowing for reduction in toxicities such as pulmonary toxicity associated with bleomycin and secondary cancer risk from agents such as procarbazine.
- Survivorship
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
$0.00
These NCCN Guidelines Insights summarize the panel’s current recommendations regarding sexual health and fertility.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 ASWB continuing education credit
- 1.00 Participation
$0.00
This adaptive learning program is designed for healthcare professionals involved in cancer pain management. Tailored to your existing knowledge, it allows you to "test out" of topics you already master. In this fully interactive course, clinicians will explore the safe and effective use of opioid analgesics, optimize non-opioid analgesics and adjuvant medications, and learn to integrate non-pharmacological approaches into comprehensive cancer pain management. Key topics include opioid safety, pain management strategies, non-opioid therapies, and holistic approaches to patient care.
- Rectal Cancer
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
$0.00
Treatment options for locally advanced or metastatic rectal cancer are evolving constantly. It is important for care teams to have an understanding of the current treatment approaches, toxicity management, and appropriate supportive care recommendations throughout a patient’s treatment course.